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Abstract 
Familial adenomatous polyposis (F AP) is an autosomal dominant colon cancer 
predisposition that results from gennline mutations in the adenomatous polyposis coli 
(APC) gene. F AP shows substantial phenotypic variability: classical F AP patients 
develop more than 100 colorectal adenomas, whereas those with attenuated FAP (AFAP) 
have fewer than 100 adenomas and those with multiple adenomas present fewer than 50 
polyps. The incidence of colorectal cancer (CRC) in Newfoundland is 27% higher than 
the national average. However, the mutation spectrum in this population has not been 
well characterized. Using direct DNA sequencing and multiple ligation-dependent probe 
amplification (MLPA), we performed mutation scanning oftheAPC gene in 48 unrelated 
Newfoundland patients with FAP/AFAP/multiple adenomas. Three previously described 
and one novel truncating mutation were identified in four PAP patients (44 %). Exon14 
deletion was detected in one patient with AFAP (5%). Two previously known missense 
variants were found in 15 individuals. In addition, eight silent variants were also 
identified in studied patients and four of them are novel. Our results suggest: 1) the 
genetic predisposition to F AP in Newfoundland population is similar to that in other 
populations; 2) gennline APC mutation may not be the major cause for AFAP; 3) the 
search for exonic deletion of the APC gene is necessary for mutation study on patients 
withAFAP. 
iv 
Keywords: familial adenomatous polyposis (F AP); attenuated familial adenomatous 
polyposis (AF AP); multiple colorectal adenomas; adenomatous polyposis coli (APC); 
DNA sequencing; multiple ligation-dependent probe amplification: MLP A; germline 
mutations; Newfoundland. 
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Chapter 1 
Introduction and Overview 
1 
Colorectal cancer (CRC) is a common cancer that affects the digestive system, and is 
responsible for 10% of all cancer deaths. Approximately two-thirds of CRCs are found in 
the large intestine and one-third in the rectum (http//www.medicinenet.com/colon 
cancer/). CRC usually develops from small noncancerous adenomatous polyps found in 
the bowel. Over time, some of these polyps become cancerous due to the sequential 
accumulation of mutations. Symptoms of CRC may include change in bowel habits, stool 
streaked or mixed with blood, discomfort or pain in the lower abdomen and tiredness 
(Canadian Cancer Society. 1993). CRC represents a major health burden in Western 
countries. Globally, CRC is the third leading cause of cancer in males and the fourth 
leading cause of cancer in females. The incidence of CRC differs around the world. It is 
common in the Western world, but rare in Asia and Africa. CRC is the second leading 
cause of cancer death in Canada (http//www.medicinenet.com/colon cancer/). The 
population of Newfoundland and Labrador has one of the highest rates of colorectal 
cancer in North America (Woods et al. 2005). 
Although the etiology of CRC remains uncertain, a number of pre-existing medical 
conditions, environmental and genetic factors can be involved. Environmental factors, for 
example, diets high in fat and low in fiber, are implicated in the pathogenesis of CRC 
(Giovannucci and Willett 1994; Winawer et al. 1997). Other risk factors for CRC include 
inflammatory bowel disease (IBD), Crohn's disease and Ulcerative colitis (UC) 
(Potter.l999). Investigations have shown that the majority of CRC cases are sporadic 
with no significant family history of CRC. However, some individuals with CRC are 
2 
shown to have an inherited susceptibility, therefore, a whole family is identified as at 
high risk. Hence, understanding an inherited susceptibility to CRC cancer is a key to the 
identification of individuals at high risk and recommendation of effective surveillance 
procedures to them. 
A scheme for types of CRC susceptibility is illustrated in Figure 1. Chance and the 
environment probably account for at least 70% of all sporadic cases, while the inherited 
susceptibilities to CRC including familial adenomatous polyposis (F AP), hereditary 
nonpolyposis colorectal cancer (HNPCC) ) and other polyposis syndromes, in total, 
account for no more than 5%. However, the remainder, perhaps about 25% represents a 
"multifactorial" contribution that has no identifiable hereditary cause (Walter and 
Bodmer. 2006). There may be other genes not yet identified, particularly those with 
reduced penetrance, or a multifactorial predisposition to CRC (Park et al.1999; Wei et al. 
2003; Woods et al. 2005). 
3 
Figure 1 Scheme for inherited susceptibility to colorectal cancer (Walter et al. 2006) 
1.1 APC-associated disorders involving an inherited susceptibility to CRC 
Adenomatous polyposis coli (APC) - associated disorders involving an inherited 
susceptibility to CRC include familial adenomatous polyposis (F AP), attenuated F AP 
(AF AP) and multiple colorectal adenomas. 
1.1.1 Familial adenomatous polyposis (FAP) 
FAP (MIM 175100) is a hereditary colon cancer syndrome, first clearly described as a 
dominantly inherited Mendelian trait by Lockhart-Mummery in 1925 (Lockhart-
Mummery. 1925). The incidence ofF AP is estimated at about 1 in 8000 live newborns, 
4 
and PAP affects both sexes equally (Peamhead et al. 2001). The most common symptoms 
of PAP are rectal bleeding, diarrhea, abdominal pain, mucous discharge and some 
symptoms related to cancer, such as weight loss, anemia, intestinal obstruction (Lynch 
and de la Chapelle. 2003). Some affected individuals may have extra-colonic features, 
such as bony growths (benign bone tumors called osteomas), which give early evidence 
that they are affected. Patients with PAP typically develop hundreds to thousands of 
adenomatous polyps throughout the entire colon and rectum. The diagnosis can be made 
earlier when fewer than 100 polyps are present if there is a first-degree relative with FAP. 
Investigations have demonstrated that almost all individuals over 40 years of age with 
PAP would inevitably develop colon cancer from these polyps unless they undertake 
prophylactic colectomy (N agase et al. 1992). Other investigators revealed that the 
penetrance of PAP for inherited cases was close to 100% in the 40's (Bisgaard et al. 
1994). Therefore, the risk of cancer is virtually 100% if the polyps are not detected and 
removed in time. Among all PAP patients, approximately 75-80% of FAP cases are 
familiar, and the 20-25% of sporadic cases are the result of de novo mutations (Bisgaard 
et al. 1994; Ripa et al. 2002). This is why some individuals with PAP have no previous 
family history of PAP. 
In addition to colorectal polyps and cancer, the variable phenotype of PAP can include 
various extracolonic manifestations (ECMs) ( Giardiello et al. 1994 ). Congenital 
hypertrophy of the retinal pigment epithelium (CHRPE) occurs in about 60% of PAP 
kindreds (Blair and Trempe. 1980). CHRPE has no impact on sight, nor any malignant 
5 
potential. It can, however, be detected by ophthalmoscopy from birth, thus helping to 
. 
identify individuals at risk ofF AP from an early age in those kindreds where CHRPE is 
present (Diaz-Llopis and Menezo.l988). Currently, it is regarded as a reliable early 
marker for FAP in relevant families (Berk et al. 1988; Valanzano et al. 1996). Other 
extra-colonic manifestations ofF AP include upper gastrointestinal tumors (adenomas or 
carcinomas of the small intestine, fundic gland polyps or carcinomas of the stomach), 
intra-abdominal desmoid tumors, osteomas (bony tumors), and benign abnormalities, 
such as dental abnormalities, or epidermal cysts (Goss and Groden. 2000; Fearnhead et 
al. 2001). Other malignancies seen in a relatively small proportion of FAP patients 
include non-medullary thyroid cancer (usually papillary thyroid cancer), hepatoblastoma, 
medulloblastoma and duodenal carcinoma (Fearnhead et al. 2001; Nandakumar et al. 
2004). Peri-ampullary carcinoma is the commonest cause of death in F AP patients who 
have undergone prophylactic colectomy (Jagelman et al. 1988; Offerhaus et al. 1992), 
making endoscopic screening of the upper gastrointestinal tract mandatory in F AP 
patients. 
Importantly, studies show that there is significant variation in the associated phenotypic 
features of F AP, both between carriers with different mutations and, to a lesser extent, 
within family members with the same mutation (Giardiello et al. 1994, Nugent et al. 
1994). Although the extra-colonic manifestations of this syndrome and its variants have 
been know for many years (Bussey. 1990), and they are to some extent helpful as 
6 
diagnostic features, the diagnosis still relies largely on the detection of numerous 
colorectal polyps during the second or third decade of life. 
F AP follows an autosomal dominant inheritance pattern, caused by germline mutation in 
the adenomatous polyposis coli (APC) gene on chromosome 5q21-22. 
Tablel. Benign and malignant lesions associated with familial adenomatous polyposis 
(Nandakumar et al. 2004). 
Malignant tumours (lifetime risk) 
Duodenal (5-11 %) 
Pancreatic (2%) 
Thyroid (2%) 
Brain (medulloblastoma) (<1 %) 
Hepatoblastoma (0.7% of children <5 yrs) 
1.1.2 Attenuated F AP (AF AP) 
Other lesions 
Osteomas 
Radiopaque jaw lesions 
Supernumerary teeth 
Lipomas, fibromas, epidermoid cysts 
Desmoid tumours 
Gastric adenomas I fundic gland polyp 
Duodenal, jejunal and ileal adenomas 
Nasopharyngeal angiofibromas 
AF AP or attenuated adenomatous polyposis coli (AAPC) is a more variable version of 
classical F AP. Affected individuals often present with fewer polyps ( <1 00 colonic 
adenomas), and tend to be older at the diagnosis of their polyps (average age of 44 years). 
However, within a family there may be variable age at onset and variable number of 
7 
polyps (from <100 to hundreds or thousands) (Spirio et al. 1999; Plawski et al. 2007). 
Individuals with AF AP are still at very high risk of developing colon cancer, but the 
average age of colon cancer diagnosis is 50-55, 10 to 15 years later than in classical F AP 
(Spirio et al. 1993; Friedl et al. 1996; Giardiello et al. 1997). In some AF AP patients, 
extra-colonic features are infrequent (Rozen et at. 1999), although other AF AP patients, 
such as those with hereditary desmoid disease, have severe extra-colonic disease (Eccles 
et al. 1996; Scott et al. 1996). The incidence and frequency of AF AP is thought to be up 
to 10% of adenomatous polyposis families (Vasen. 2000). However, the true incidence 
and frequency of AF AP remains unknown. Similar to F AP, AF AP follows an autosomal 
dominant inheritance pattern, and is caused by germline mutations in the APC gene. 
1.1.3 Multiple colorectal adenomas 
Patients with multiple colorectal adenomas have a phenotype like AF AP, with 3 to 99 
polyps throughout the colorectum. Affected individuals are also at high risk of 
developing colorectal cancer. The condition can be inherited as a Mendelian trait, either 
autosomal dominant or recessive, but can also occur in the form of isolated cases. Some 
patients with the multiple adenoma phenotype are classified as having attenuated 
polyposis (AFAP) owing to a germline APC mutation, usually in exons 1-4, exon 9, or 
the 3'-end (distal to codon 1580) (Knudsen et al. 2003; Young et al. 1998; Soravia et al. 
1998; Sieber et al. 2006). However, most multiple adenoma patients have no identifiable 
8 
germline APC mutations and do not have the extracolonic manifestations sometimes 
associated with AF AP (Vasen. 2000; Sieber et al. 2002). 
Studies have shown that a substantial proportion of multiple adenoma patients are 
associated with a novel type of DNA repair defect. Recent studies indicate that mutations 
in the base excision repair gene- human MutYhomologue (MYH) cause a new autosomal 
recessive form of polyposis characterized by the presence of a variable number of 
colorectal adenomas, referred to as MYH associated polyposis (MAP). Oliver et al (2003) 
reported that of 152 patients with 3 to 100 adenomas, about 5% had disease attributable 
to MYH mutations. However, they frequently do not have an autosomal dominant family 
history of polyposis, (Jones et al. 2002; Sieber et al. 2003; Galiatsatos et al. 2006). 
The cause of the phenotype of multiple colorectal adenomas is probably genetically 
heterogeneous. It is difficult to distinguish between patients with APC mutations and 
those with biallelic MYH mutations on the basis of clinicopathological features, although 
family history can be useful. Therefore, the cause of the phenotype of multiple colorectal 
adenomas should be elucidated by molecular classification. Patients with multiple 
adenomas should be classified as having APC-associated or MYH-associated polyposis. 
1.2 Model for genetic alterations in the developments of APC-associated colorectal 
cancer 
9 
It is well established that development of CRC is a complex and multi-step process, in 
which several defective genes coordinate with each other in tumorigenesis. CRC usually 
develops from an adenoma (commonly known as a polyp) on the inner lining of the 
gastrointestinal tract. Abnormal cells arising within these adenomas will eventually 
progress to adenocarcinomas through histologically distinct stages, the "adenoma to 
carcinoma sequence" (O'Brien et al. 1990, Muto et al. 1995). Fearon and Vogelstein 
(1990) proposed a model that has improved the understanding of the molecular genetics 
of sporadic CRC (Figure 2). This model states that a series of genetic changes take place 
in order for the development of CRC. The process includes the interdependence of 
different pathways and involvement of many more gene mutations than previously 
recognized (Bodmer. 1996; Ilyas et al.1999). These changes include major chromosomal 
alterations, germline and somatic mutations. Loss of heterozygosity (LOH) commonly 
but variably occurs on chromosomes 5q, 8p, 17p, 18q and 22q during the adenoma-
carcinoma sequence (Nowak. 2002). Mutations occur in tumor suppressor genes (e.g. 
APC, DCC, SMAD4, and P53) and proto-oncogenes (e.g. K-ras), which are also involved 
in the development of hereditary CRCs (Fearon and Vogelstein. 1990; Fodde. 2002). The 
APC gene, the primary cause of F AP, is described as a gatekeeper, because evidence 
reveals that mutations in this gene perhaps set a stage for mutations in other genes such as 
K-ras, DCC, andp53 (Groden et al. 1991; Nishisho et al. 1991). An APC gene mutation 
appears to be an early and critical event in the progression of normal colonic epithelium 
to adenoma, and then to carcinoma by disturbance of proliferation regulation of colonic 
cells (Kinzler and Vogelstein. 1996; Fearnhead et al. 2001 ). However, this genetic model 
10 
is also controversial. Smith et al (2002) analyzed the mutation spectra in APC, p53 and 
K-ras in more than 100 patients with colorectal cancer. In contrast to the prediction of the 
sequential model of mutation accumulation, only 6.6% of tumors were found to carry 
mutations in all three genes, with 38.7% of tumors containing mutations in only one of 
the three genes. The most common combination of mutations was p53 and APC (27 .1 %), 
whereas, mutations in K-ras and p53 co-occurred less frequently than expected by 
chance. 
Lamlum et al (1999) found that in patients carrying an APC germline mutation, tumor 
development starts in the polyps when the remaining wild-type APC allele is mutated by 
somatic mutation which is consistent with Knudson's ''two hit" hypothesis. However, 
some contradictary observations have also been reported. Polakis (1997) noted that in 
some circumstances one defective gene copy alone may be enough to trigger the cancer 
development, because the mutant APC gene product can influence the function of the 
wild-type gene product, resulting in the total loss of APC function (dominant negative). 
11 
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Figure 2. Model for genetic alterations in the development of colorectal cancer (Fearon 
and Vogelstein. 1990) 
1.3 The APC gene and the gene product 
1.3.1 APC gene 
Herrera and Sandberg in 1986 demonstrated an interstitial deletion of the chromosomal 
band 5q21 in a patient with colorectal polyposis and mental retardation, but no family 
history ofF AP (Herrera et al. 1986). This observation greatly helped to localize the APC 
gene in 1987 (Bodmer et al. 1987). Subsequent DNA linkage analysis of families with 
FAP led to the refined mapping oftheAPC gene to 5q21-22 (Bodmer et al. 1987; Leppert 
et al. 1987) (Figure 3). Loss of heterozygosity (LOH) studies had already strongly 
indicated the involvement of this locus in a high proportion of sporadic colorectal 
carcinomas (Solomon et al. 1987). Studying a smaller deletion, the location of APC gene 
12 
was refined by Groden et al (1991) and Kinzler et al (1991). Ultimately, the APC gene 
was cloned, characterized, and identified as the specific gene responsible for F AP by 
means of positional cloning (Joslyn et al. 1991; Nishisho et al. 1991). 
Figure 3. Chromosomal location oftheAPC gene 
The APC gene has 15 exons with an 8535 base pair open mRNA reading frame (VanES 
et al. 2001; Fearnhead et al. 2001; Foulkes et al.l995). Exon 15 is the largest exon (6500 
bp length), comprising more than 75% of the coding sequence of APC (Powell et al. 
1992; Horii et al. 1993 ). The APC gene encodes for a 312 KDa protein that consists of 
2843 amino acids (Van Es et al 2001; Fearnhead et al. 2001; Foulkes. 1995). The 
transcriptional initiation of APC occurs at three sites in two distinct non-translated exons 
at the 5-prime end of the gene (Horii et al. 1993). At least five different forms of 5-prime 
noncoding sequences have been identified, which are generated by alternative splicing 
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(Horii et al. 1993). The splicing mechanism appears to be regulated in a tissue-specific 
fashion, and one transcript, expressed exclusively in brain, contains an extra exon. A 
diagram of the structure oftheAPC gene is presented in Figure 4. 
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Figure 4. APC gene structure, eDNA (below) and important protein motifs (above). 
(VanEs et al2001) 
1.3.2 The APC protein 
The APC protein is a multidomain protein containing 2,843 amino acids, an:d expressed 
constitutively in a variety of fetal and adult tissues, including mammary and colorectal 
epithelium (VanES et al. 2001). Within a cell, the APC protein exists predominantly in 
the cytoplasm, although nuclear localization has also been reported. It was reported to 
occur in several isoforms within cells, probably as a result of alternative splicing at the 
mRNA level (Sulekova et al. 1995). The APC protein is multifunctional and contains 
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several amino acid motifs and domains, which interact with numerous other molecules 
having diverse functions within the cells. The structure of the APC protein with different 
protein interaction domains is illustrated in Figure 5. At the N-terminal site, the APC 
protein contains oligomerization and Armadillo-repeat binding domains. At the C-
terminal site, there are end-binding protein 1 (EB 1) and human discs large tumor 
suppressor protein (hDLG) binding domains. Furthermore, the APC protein binds 13-
catenin through two motifs: the first contains three imperfect 15 amino acid repeats and 
the second comprises seven repeats of 20 amino acids, involved in the negative regulation 
of ~-catenin protein levels in cells (Suet al. 1993; Rubinfeld et al. 1993; Rubinfeld et al. 
1996; Rubinfeld et al. 1997). 
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Figure 5. Structural features of the APC protein (Narayan et al. 2003) 
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1.3.3 Functions of the APC protein 
The APC protein is multifunctional and plays a major role in tumor suppression by 
antagonizing the Wnt-signaling pathway. Inappropriate activation of this pathway 
through loss of APC function contributes to cancer progression. APC also has roles in cell 
migration, adhesion, chromosome segregation, spindle assembly, apoptosis, and neuronal 
differentiation. 
i) APC protein plays a role in the control of cell proliferation 
The APC protein plays an integral role in the Wnt-signalling pathway, especially in 
regard to the degradation of ~-catenin within the cell cytoplasm (Bienz. 1999; Willert et 
al. 1998). The APC protein binds ~-catenin and regulates intracellular levels of ~-catenin 
through Wnt-signaling pathway, which regulates the proliferation, migration, and 
differentiation of cells in the intestinal epithelium. The details of Wnt-signaling pathway 
are illustrated in Figure 6. 
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A. Normal colonic epithelia) cells B. Colon cancer cells 
~ ~ 
Controlled cell growth Uncontrolled cell growth 
Figure 6. A model for the Wnt-signaling pathway (Narayan et al. 2003) 
ii) The APC protein is involved in actin cytoskeletal integrity, cell-cell adhesion and cell 
migration 
Actin cytoskeletal integrity has a very important role in maintaining the shape and 
adherence junctions of cells. If the balance in actin cytoskeletal integrity is destroyed, it 
will affect intercellular adhesion and cell migration. The APC protein is indirectly linked 
to actin cytoskeleton with ~-catenin and a-catenin establishing a bridge between them 
(Serrano et al. 1997). It also interacts with E-cadherin through ~-catenin. This forms a 
cell-cell adhesion complex with actin cytoskeleton, which maintains stable cell-cell 
adhesion (Polakis. 2000; Gumbiner. 2000) (Figure 7). 
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The APC protein also contributes to orderly migration of intestinal cells within the 
intestinal crypt (Moss et al. 1996; Mahmoud et al. 1997). 
A. Normal colonic epithelial cells B. Colon cancer celts 
Figure 7. Mutations in APC gene impair actin cytoskeletal integrity, cell-cell adhesion 
and cell migration properties of colon cancer cells (Narayan et al. 2003) 
iii) The APC protein is associated with chromosomal instability (CIN) 
Studies demonstrate that APC acts as a linkage between microtubules and chromosomes, 
which may facilitate the spindle formation. Therefore, it is crucial in maintaining normal 
segregation of chromosomes at mitosis (Kaplan et al. 2001) (Figure 8). 
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Figure 8. Chromosomal instability (CIN) in cells carrying mutations in APC gene 
(Narayan et al.2003) 
iv) The APC protein has a role in the regulation of apoptosis 
It is possible that APC may play an indirect role in regulation of apoptosis, as the 
restoration of expression of wild-type APC in colorectal cancer cells lacking endogenous 
APC expression has been reported to promote cell death through apoptosis (Morin et al. 
1996). It is likely that APC may stimulate the apoptosis of cells by an indirect influence 
on intercellular adhesion and the extracellular matrix (ECM). 
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1.4 Molecular pathogenesis ofF API AF API multiple colo rectal adenomas 
1.4.1 Germline mutations of APC 
In approximately 80% of individuals with F AP, germline mutations can be identified 
within the APC gene (Kinzler and Vogelstein.1996; Miyoshi et al. 1992; N agase et 
al.1992; Powell et al. 1993). The spectrum of identified mutations is extremely 
heterogeneous. To date, more than 1 000 different germline mutations in the human APC 
gene have been compiled from the literature in online databases 
(http://perso.curie.fr/tsoussi, and http://www.cancer-genetics.org). In the majority of 
cases, the reported mutations cause a premature truncation of the APC protein (94%), 
usually through either a nonsense mutation (33%), or a frameshift mutation (6% small 
insertions, 55% small deletions) (Beroud and Soussi. 1996). Therefore, loss of function in 
one APC allele is suggested to underly the genetic susceptibility for F API AF AP /multiple 
adenomas. The reported germline mutations in APC are unevenly distributed over the 
entire gene sequence (Figure 9), and are predominantly located in the 5' end of the gene, 
particularly at the 5' end of exon 15 between codon 713 and 1597, referred to as the 
mutation cluster region (MCR) (Nagase and Nakamura. 1993). The most common 
germline APC mutations are the two 5-bp deletions, which result in frameshift mutations 
at codon 1061 (c.3183_3187delACAAA) and 1309 (c.3927_3931delAAAGA) (Beroud 
and Soussi. 1996). These two deletions account for about 11% and 17% of all germline 
mutations, respectively (Groden et al. 1993; Fearnhead et al. 2001). The cause of 
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mutational hotspots at these codons may be the repeat sequences located near these two 
deletions, which can cause misalignment errors in DNA replication (Mandl et al. 1994; 
De Rosa et al. 2003 ). 
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Figure 9. Distribution of identified APC germline mutations in 327 of 680 F AP families 
(Friedl et al. 2001) 
Large genomic rearrangements are also found in patients with F AP, accounting for 
approximately 8-12% FAP cases (Sieber et al. 2002; Bunyan et al. 2004; Aretz et al. 
2005; Michils et al. 2005). These genomic rearrangements may be large enough to be 
cytogenetically visible or may only involve one or a few exons. Cytogenetically visible 
interstitial deletions of chromosome 5q22, which include the APC gene, have been 
reported in individuals with adenomatous polyposis and mental retardation (Pilarski et al 
1999). However, the majority of reported genomic arrangements associated with 
FAP/AFAP/multiple adenomas are not cytogenetically visible but are sometimes 
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detectable using fluorescence in situ hybridization (FISH). Deletions of ex on 4, 11, 12, 
14, and 15 (Suet al. 2002; Cao et al. 2001; Sieber et al. 2002), and duplication of exon 4 
( McCart et al. 2006) have been described. Of these rearrangements, partial or total 
deletions of ex on 14 are the most frequent (Su et al. 2000; Cao et al. 2001; Sieber et al. 
2002). These large deletions are found more frequently in patients with classical F AP 
than in patients with AF AP (Sieber et al. 2002, Su et al. 2002). In Michils study (2005), 
large deletions were identified in 15% of classical F AP patients ( 4 of 27), but were absent 
in AF AP patients (0 of 28). However, Su et al (2002) identified deletion of the entire 
exon 15 of APC (caused by 56 kb and 73 kb deletions) in two patients. One patient 
presented with the typical F AP phenotype, whereas the other exhibited an AF AP 
phenotype. 
Missense or silent variations are rarely associated with F AP. Two missense variants in 
APC, 11307K and E1317Q, are reported to be linked to an increased risk of colorectal 
adenoma and carcinoma. The mutation 11307K is reported to create a hypermutable 
region that does not lead to classic FAP, 'but causes an increased risk of colon cancer 
(Laken et al 1997). Approximately 6% of all individuals of Ashkenazi Jewish ancestry 
have the I1307K mutation. These individuals are predisposed to developing only a few 
colon polyps, but have an approximate 10-20% lifetime risk of developing colon cancer. 
The E1317Q mutation may be associated with a predisposition to colon adenomas and/or 
colon cancer (Frayling et al 1998; Lamlum et al 2000; Popat et al 2000 and Hahnloser et 
al2003). 
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1.4.2 Genotype-phenotype correlations in FAP 
Correlations between the location of a particular gennline APC mutation and clinical 
features have been suggested by a large number of studies. Mutations in the central 
region of the APC gene have been correlated with a severe phenotype with thousands of 
polyps at a young age and with additional extracolonic manifestations (Caspari et al. 
1995; Miyoshi et al. 1992). The most frequent mutation in the APC gene is located in this 
region at codon 1309. Mutations at this codon lead to PAP-related symptoms because of 
multiple colorectal adenomas at an average age of 20 years (Friedl et al 2001; Bertario et 
al 2003). Individuals with mutations between codon 168 and 1580 (excluding 1309) 
presented with symptoms at an average age of 30 years, and individuals with mutations 5' 
of codon 168 and 3' of codon 1580 presented with symptoms at an average age of 52 
years (Friedl et al 2001). Profuse polyposis (an average of 5000 polyps) has been 
associated with mutations between codons 1250-1464 (Nagase et al1992). 
Mutations in the first or last third of the gene are associated with an attenuated polyposis 
with a later onset and a small number of polyps (Spirio et al. 1993; van der Luijt et al. 
1996; Friedl et al. 1996). The AF AP associated regions in the APC gene include the 
5' -end ( codons 1-177 in exons 1-4), the alternatively spliced part of ex on 9 ( codons 
311-408), and the 3 '-end (distal to codon 1580) (Knudsen et al. 2003; Young et al. 1998; 
Sora via et al. 1998; Sieber et al. 2006) (Figure 1 0). Mutations at the 5' end of APC have 
been reported as the most frequent mutations associated with the AF AP. It was 
speculated that the wild-type APC protein might be unable to fonn dimers with the very 
small truncated proteins generated from 5' end mutations, thus, causing an attenuated 
phenotype (Dobbie et al. 1994). This speculation was supported by another study, in 
which an identical 5' splice-site acceptor mutation (in APC intron 3) was detected in five 
attenuated FAP families from Newfoundland resulting from a founder effect (Spirio et al. 
1999). 
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Figure 10. Attenuated F AP -associated regions in APC gene (Sieber et al. 2006) 
Prominent extracolonic manifestations often correlate, but not completely, with more 
distal APC gene mutations. Mutations between codons 1444 and 1580 are associated with 
a higher incidence of desmoid tumors (Caspari et al 1995; Davies et al 1995). Mutations 
between codons 463 and 1387 are associated with congenital hypertrophy of the retinal 
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pigment epithelium (CHRPE) (Olschwang et al. 1993; Caspari et al. 1995), whereas, 
absence of CHRPE was correlated with mutations between codons 1444 and 1578 
(Caspari et al 1995; Davies et al 1995). Individuals with mutation between codons 976 
and 1067 were reported to have a fourfold increased risk in duodenal adenomas (Bertario 
et al. 2003). Hepatoblastoma and brain cancer were seen only in individuals with 
mutations in codons 457-1309. Mutations in codons 177-452 seem to be associated with 
absence of CHRPE, osteomas, hepatoblastomas, periampullary region tumors, or brain 
cancers. 
1.4.3 Molecular genetic testing for mutations in APC gene 
Because germline mutations of APC gene are well known to cause genetic susceptibility 
to FAP and AFAP, detection of APC germline mutations could be a powerful tool for 
clinical diagnosis or predictive testing for FAP/AFAP/multiple adenomas. Testing for 
known mutations in APC genes has been routinely offered in the majority of molecular 
diagnostic laboratories in North America, which is mainly used in confirmative, 
predictive and prenatal diagnosis of APC-associated polyposis conditions. 
Mutation scanning of the entire APC gene by using direct DNA sequencing or other 
mutation scanning methods can detect up to 90% of mutations. The majority of germline 
mutations identified from individuals with FAP/AFAP/multiple adenomas will lead to 
truncation of the APC protein, which forms the basis for their detection by the protein 
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truncation test (PTT) (Powell et al. 1993). Therefore, PTT is commonly used for 
searching for APC germline mutations in most clinical diagnostic laboratories. 
Approximately, 80% of individuals with F AP are found to be positive for PTT. 
Duplications and deletions in the APC gene can be detected by using methods including 
Southern blot analysis, multiplex ligation-dependent probe amplification (MLP A), and 
quantitative PCR. However, these APC duplication/deletion analyses are still more 
commonly performed as a research protocol. 
Germline mutations identified from the APC gene are highly heterogeneous and widely 
spread throughout the very large APC gene. Because of this, targeted mutation analysis, a 
common and efficient method for mutation analysis in molecular genetic diagnosis is not 
feasible. Although mutation scanning of the entire APC gene by using direct sequencing 
can detect up to 90% of mutations, this is time-consuming, costly and labor-intensive. 
Therefore, it is difficult for direct se9uencing to be applied as a routine test in clinical 
service. Moreover, direct sequencing analysis cannot detect large genomic 
rearrangements or possible transcription defects. Southern blot is the traditional but still 
commonly used molecular method for analyzing large genomic rearrangements. The 
detection of these genomic rearrangements is based on the determination of the gene 
dosage changes. However, hybridization-based techniques are relatively expensive, time-
consuming and large amounts of high-quality DNA are needed. Multiplex amplification 
and probe hybridization (MAPH) and multiplex ligation-dependent probe amplification 
(MLP A) are recently developed techniques used for facilitating measurement of 
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alterations of gene dosage, especially for detecting gene dosage changes in much smaller 
fragments (Armour et al. 2000; Schouten et al. 2002). These techniques have been 
successfully used to screen for deletions/duplications of the APC gene in families with 
F API AF AP, in which APC point mutations are not found. 
1.5 FAP/AFAP/multiple colorectal adenomas in the Newfoundland population 
The population of the island of Newfoundland consists mainly of descendants of English 
and Irish settlers who arrived in the 1 ih and 18th centuries (Martin et al. 2000). The 
geographical and social isolation of this island has ensured very little inward migration 
for several hundred years (Bear et al. 1987) and thus has lead to a small population 
(530 000 individuals; Statistics Canada 2001) with a relatively homogenous genetic 
background. Founder mutations have been demonstrated in a number of genetic diseases 
including F AP (Spirio et al. 1999). 
Newfoundland has the highest incidence of CRC among all Canadian provinces, which is 
27% higher than the national average (Canadian Cancer Statistics. 2003). Currently, at 
least 25 Newfoundland families with FAP/AFAP/multiple adenomas have been clinically 
identified, and there are approximately 50 families, which are suspected to have FAP, 
AF AP or multiple colorectal adenomas. 
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1.6 Rationale for the proposed study 
The spectrum of APC mutations in a large number of families with FAP/AFAP/multiple 
adenomas in the Newfoundland population remain unknown: Searching for germline 
mutations of the APC gene in the Newfoundland population has only been performed in a 
limited number of families with clinically diagnosed F AP or AF AP or multiple adenomas 
and three mutations have been identified. However, molecular defects in the majority of 
Newfoundland families with FAP I AFAPI multiple adenomas have not been identified. 
Genetic testing is therefore not possible for these families with unidentified mutations. 
Members ofF AP or AF AP or multiple adenomas families are at risk of developing colon 
cancer, and identification of genetic predisposition will be of clinical benefit: Individuals 
with an APC germline mutation will develop multiple polyps in the colon and have an 80 
-100% lifetime risk that one or more polyps will progress to colon cancer. Morbidity and 
mortality can be significantly reduced if at-risk individuals are followed with a 
colonoscopy-screening program, and the colon is removed surgically when multiple 
polyps are identified. Since FAP/AFAP is an autosomal dominant condition, each first-
degree relative of an affected person has a 50% chance of having inherited the same 
mutation. The screening program is most efficient when the family-specific mutation in 
the APC gene is known and genetic testing is offered to those at-risk. Then colonoscopy 
screening is only required by those who have the identified mutation. Therefore, genetic 
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testing and management that will detect or avoid CRC cancer in these families are very 
cost effective. 
Identification of non-carriers for the family germline mutation will also have clinical and 
social benefits: Many individuals in high-risk families are not at increased risk ofF AP or 
AF AP or multiple adenomas because they did not inherit the "family" mutation (non-
carriers). They usually suffer an unnecessary physical challenge from routine 
colonoscopy screening if their non-carrier status is unknown. For those who did not 
inherit the family mutation, genetic testing will allow the tested individual to have a 
permanent release from psychosocial and physical suffering resulting from unnecessary 
routine colonoscopy and worry about cancer risk. There will also be savings in health 
care costs when unnecessary colonoscopy screening and clinical follow-up can stop. 
The purpose of the study: The proposed project is a) to perform a mutation study in all 
Newfoundland families with patients who have clinical indication ofFAP/AFAP/multiple 
adenomas; b) to understand the population genetics ofFAP/AFAP/multiple adenomas in 
Newfoundland, its origin, and potentially a better understanding of the phenotypic 
variation associated with particular mutations in this isolated population. Mutation 
screening by using a combination of direct sequencing analysis and MLP A analysis will 
allow us to identify all possible point mutations and also to detect large genomic 
rearrangements in the APC gene. Successful identification of these mutations will be of 
long-term benefit to the Newfoundland population because a) genetic predisposition 
?Q 
screening can be offered to family members who are at risk for F AP; b) definitive genetic 
counseling and clinical guidance can then be provided to at-risk individuals who have the 
genetic testing. 
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Chapter 2 
Patients and Methods 
l1 
2.1 Clinical criteria used in phenotype classification 
i) Classical F AP 
• Individual with or without an autosomal dominant family history of CRC and/ or 
polyps who has more than 100 colorectal polyps. 
• Or, individual with an autosomal dominant family history of CRC and/ or polyps 
and I or extra colonic features associated with F AP who has fewer than 100 
colorectal polyps before age of 35 years. 
ii) Attenuated F AP 
• Individual who has an autosomal dominant family history of CRC and/ or polyps 
with a variable number of polyps (fewer than 20 polyps to 100 polyps), variable 
age at onset, and variable location of polyps. 
• Or, individual with no family history who has 10-100 polyps 
iii) Multiple colorectal adenomas 
Patients of this category include those who have family history of CRC 
and/ or polyps (<50 polyps), but do not meet the criteria either for classical F AP or 
for AF AP. The majority of these patients have fewer than 1 0 polyps. 
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2.2 Patients 
In total, 48 unrelated patients (29 males, 19 females) were involved in present study. 
These patients represent 48 different families from Newfoundland. All patients had been 
examined by colonoscopy or had a colectomy, and histological studies, and the diagnoses 
of classical F AP, AF AP or multiple colorectal adenomas for these patients were 
determined using the clinical criteria mentioned above. 
Of the 48 selected patients, nine were classified as classical FAP; 20 as AFAP; 19 as 
multiple adenomas. The details of clinical features from all of the patients are presented 
in Table 2. Two healthy individuals (unaffected with any cancer) were included in the 
study panel as healthy controls. 
The present study was approved by the Human Investigations Committee of the Faculty 
of Medicine, Memorial University of Newfoundland, and the Health Care Corporation of 
St. John's. All informed consents for genetic testing were obtained. 
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Table 2. Clinical characteristics of the 48 patients tested for APC germline mutations 
Patient # of polyps/ age at CRC/ age at Extracolonic Family Phenotype 
No diagnosis of polyps diagnosis of CRC Manifestation History 
75 1 00-1 000/ 63 No No FAP 
195* >1000/ 57 No No FAP 
222 >1000/ 36 Yes/ 49 desmoids,osteomas,epidermoid Yes FAP 
884 >1000/ 51 Yes/51 No FAP 
1168 100-1000/ 27 No CHRPE, others Yes FAP 
1213 1 00-1 000/ 40 Yes/ 40 Yes FAP 
10912 100-1000/ II No CHRPE, Yes FAP 
11572 >1000/ 31 No duodenal polyposis No FAP 
12426 10-100/25 No desmoids, other Yes FAP 
18 10-100/54 Yes/ 54 gastric adenomas Yes AFAP 
648* 10-100/45 Yes/ 45 No AFAP 
954 150/56 Yes/ 56 Yes AFAP 
1101 10-100/47 Yes/47 other Yes AFAP 
1167 200/59 Yes/ 59 Yes AFAP 
1212 10-100/77 No Yes AFAP 
1215 10-100/46 No Yes AFAP 
1320 150/44 Yes/44 Yes AFAP 
1606 10-100/52 No Yes AFAP 
2052 10-100/62 Yes/62 Yes AFAP 
10620 100/45 Yes/ 45 other Yes AFAP 
11160 10-100/51 No duodenal polyposis Yes AFAP 
11417 10-100/57 No Yes AFAP 
11468 150/25 No Yes AFAP 
11988 <10/ 60 Yes/ 69 Yes AFAP 
12071* 10-100/38 No Yes AFAP 
12082 10-100/52 No other Yes AFAP 
12127 10-100/29 No Yes AFAP 
12204 10-100/40 No other Yes AFAP 
12597 10-100/ 55 Yes/ 65 Yes AFAP 
63 10-100/71 Yes/71 Yes MA 
213 <10/ 51 No Yes MA 
415 <10/ 58 Yes/ 58 No MA 
464 10-100/54 Yes/ 56 Yes MA 
931 0/44 Yes/44 Yes MA 
1096 10-100/54 Yes/54 Yes MA 
1307 <10/54 Yes/56 Yes MA 
1349 10-100/47 No Yes MA 
1685 0145 Yes/45 Yes MA 
1744 Unknown Yes/43 Yes MA 
11069 10-100/52 No Yes MA 
11102 <10/ 43 No other Yes MA 
11308* <10/61 Yes/ 61 Yes MA 
11431* 10-100/58 No other Yes MA 
11867 <10/ 79 Yes/ 79 Yes MA 
12174 <10/63 No Yes MA 
12566 0/70 Yes/ 70 Yes MA 
12603 <10/54 Yes/ 57 Yes MA 
12905 <10/ 57 Yes/ 57 No MA 
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FAP indicates familial adenomatous polyposis 
AF AP indicates attenuated familial adenomatous polyposis 
MA indicates multiple adenomas 
Asterisk(*) indicates that DNA samples were not available for MLP A test 
2.3 DNA extraction from whole blood 
Genomic DNA was extracted from the white cells of venous blood, which was collected 
from subjects in Na2-EDTA vacutainer tubes. DNA extraction was performed using a 
salting-out method described by Miller et al (1988) with the following modifications: 
5 ml ofTKMt buffer (10 mM Tris, 10 mM KCL, 10 mM MgCh, 2 mM EDTA, pH 7.6) 
was added to the blood, followed by 1.25 ml of a membrane-lysing agent, 10% lgepal 
(Sigma - a non-ionic detergent; Octylphenyl-polyethylene glycol). The tube was mixed 
by inversions, and then centrifuged at 2200 rpm for 1 0 minutes at room temperature. The 
supernatant was poured off and the nuclear pellet was saved. The pellet was then washed 
twice with 1 Oml of TKM1 buffer, re-suspended in 0.8 ml of TKM2 buffer (1 OmM Tris 
HCl, 10mM KCl, 10mM MgCh, 4M NaCI, 2mM EDTA pH7.6), and transferred to a 1.5 
ml microcentrifuge tube containing 50 f..ll of 10% SDS, and then incubated for 30 minutes 
at 50 °C for complete nuclear membrane lysis. Following this incubation, 0.4 ml of 5M 
NaCl was added to the tube, mixed and centrifuged at 14000 rpm for 20 minutes. The 
supernatant was saved and transferred to a 15 ml centrifuge tube, and 2.4 ml of 90% 
ethanol was added to precipitate DNA. The precipitated DNA was transferred to an 
eppendorf tube and dissolved in 100-200 Jll TE buffer (IOmM Tris-HCl, 0.2 mM 
Na2EDTA, pH 7.5). Then the concentration was determined by UV spectrophotometry 
measured absorbance at 260 and 280. 
2.4 Mutation scanning- direct DNA sequencing 
2.4.1 Primers for PCR amplification 
Direct DNA sequencing was used to perform germline mutation screening for the APC 
gene in the present study. The genomic DNA sequence of the APC gene was amplified in 
a total of 38 PCR amplicons, which cover the entire coding region, the splice sites and 
partial 5' and 3' non-coding regions of the APC gene. The sequences of all 38-paired 
primers used for APC gene analysis are presented in Table 3. All the primers are 
described from 5' 7 3'direction. The sequences of the majority of the primers were 
reported in a previous study (Groden et al. 1991). The remainder (denoted with *)were 
designed using the computer software of IDT's Primer Quest 
(http://scitools.idtdna.com/primerquest/) (All primers were purchased from Applied 
Biosystems Foster City, CA). 
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Table 3. PCR primers for sequence analysis of 15 exons of the APC gene 
Ex on Forward primer 5'-3' Reverse primer 5'-3' 
1* ccactgtttcatcctcttagatgc atcactgtactgaggcaaggt 
2* gtgcgtgctttgagagtgatctga gcttgttgctattctgccagtcac 
3* tttaccctgacccaagtggac cgtttcctgggattctgaagacct 
4* ttagcactttaggtagagaagtttgc caagcactaaagctggtttgttt 
5* ggatccagattgagtctgacacct tagatggtggtcttccggtagcta 
6 ggtagccatagtatgattatttct ctacctatttttatacccacaaac 
7 aagaaagcctacaccatttttgc gatcattcttagaaccatcttgc 
8* cagtctttggttaagtccattctgc cttgaactcctggcctcaagtgat 
9-1 agtc gtaattttgtttctaaactc tgaaggactcggafftcacgc 
9-2 tcattcactcacagcctgatgac gctttgaaacatgcactacgat 
10 aaacatcattgctcttcaaataac taccatgatttaaaaatccaccag 
11 gatgattgtctttttcctcttgc ctgagctatcttaagaaatacatg 
12* gaccaaggcaagtgttacacacaca tgcagtgagctgagattgcacaac 
13* agtcaccacggctagccagaattt aggttgcagtgagccaagatcaga 
14 tagatgacccatattctgtttc tagatgacccatattctgtttc 
15-1 gttactgcatacacattgtgac gctttttgtttcctaacatgaag 
15-2 agtacaaggatgccaatattatg acttctatctttttcagaacgag 
15-3 atttgaatactacagtgttaccc cttgtattctaatttggcataagg 
15-4 ctgcccatacacattcaaacac tgtttgggtcttgcccatctt 
15-5 agtcttaaatattcagatgagcag gtttctcttcattatattttatgcta 
15-6 aagcctaccaattatagtgaacg agctgatgacaaagatgataatg 
15-7* agaggcagaatcagctccatccaa actgcatggttcactctgaacgga 
15-8 atctccctccaaaagtggtgc tccatctggagtactttccgtg 
15-9* agctcaaaccaagcgagaagtacc acaatacacccgtggcaatcatcc 
15-10 cccagactgcttcaaaattacc gagcctcatctgtacttctgc 
15-11 ccctccaaatgagttagctgc ttgtggtataggttttactggtg 
15-12 acccaacaaaaatcagttagatg gtggctggtaactttagcctc 
15-13 atgatgttgacctttccaggg attgtgtaacttttcatcagttgc 
15-14 aaagacataccagacagaggg cttttttggcattgcggagct 
15-15 aagatgacctgttgcaggaatg gaatcagacgaagcttgtctagat 
15-16 ccatagtaagtagtttacatcaag aaacaggacttgtacttgagga 
15-17 cagccccttcaagcaaacatg gaggacttattccatttctacc 
15-18 cagtctcctggccgaaactc gttgactggcgtactaatacag 
15-19 tggtaatggagccaataaaaagg tgggagttttcgccatccac 
15-20 tgtctctatccacacattc gt atgtttttcatcctcactttttgc 
15-21 ggagaagaactggaagttcatc ttgaatctttaatgtttggatttgc 
15-22 tctcccacaggtaatactccc gctagaactgaatggggtacg 
15-23 caggacaaaataatcctgtccc attttcttagtttcattcttcttcctc 
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2.4.2 PCR amplification and product purification 
DNA PCR amplification was carried out in a total of 25 )ll of PCR reaction consisting of 
approximately 100-200 ng genomic DNA, 2.5 )ll dNTPs (10 mM), 0.5 )ll (2.5 )lMI)ll) 
each primer and 0.3 )ll (5 units /)ll)Taq DNA polymerase, 1.5 )ll (50mM) MgCh, 2.5 )ll 
( 10 mM KCl, 10 mM (NH4)2S04, Tris-HCl, 2 mM MgS04, 0.1% Triton X-1 00 PH 8.8) 
lOx buffer (All dNTPs, PCR buffer and DNA polymerase were purchased from Applied 
Biosystems Foster City, CA). The PCR amplifications were performed by using the 
Eppendorf MasterCycler (Eppendorf AG, Hambeug, Germany). All samples were 
amplified by using the conditions as follows: 95 °C for 5 min followed by 35 cycles of94 
°C for 1 min, 50 °C -58 °C for 1 min, 72 °C for 1 min, plus a final extension of 72 °C for 
lOmin. 
The quality of the DNA amplification was analyzed by electrophoresis of the PCR 
products on 2 % ethidium bromide stained agarose gels, which were visualized under UV 
transilluminator. The presence of bands of the appropriate length confirmed the 
successful PCR amplification. 
Purification of PCR products was carried out using the QIAquick Multiwell PCR 
purification kit (Qiagn) on a Mastercycler. Briefly, each 5 )ll of PCR amplification 
mixture was mixed with 1 )ll ( 10 units I )ll) of Exonuclease I and 2 )ll (1 unit I ul) of 
Shrimp Alkaline Phosphatase (SAP), to remove excess primers and free dNTPs. The 
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reaction was carried out at 37 °C for 15 min, and terminated by heating at 80 °C for 15 
min (inactivation of the enzyme within the reaction). 
2.4.3 Taq-polymerase catalyzed cycle sequencing using fluorescent-labeled dye 
terminator reactions and post-reaction cleanup 
Cycle sequencing was performed in a 20 !ll PCR reaction by using CEQ DTCS-Quick 
Start Kit (Dye Terminator cycle sequencing) on a Mastercycler according to the 
manufacturer's instructions, with certain modifications. Briefly, each 4 !ll of purified 
PCR product was added to 16 !ll of mixed solution containing DNA polymerase, CEQ 
Dye terminators (ddUTP, ddUTP, ddGTP, ddCTP, and ddATP), dNTPs, sequencing 
reaction buffer (Applies Biosystems), and primers. The reaction was then subjected to 95 
°C for 4 min, as an initial denaturing step, followed by 40 cycles of 95 °C for 30 sec, 55 
°C for 30 sec, and 72 °C for 1 min. 
Subsequently, ethanol precipitation was used to clean up the free ddNTPs and the 
residual salts from each reaction. Briefly, the sequencing products were transferred to a 
0.5 ml microcentrifuge tube containing 5 !ll of stop solution (2/ll of3 M NaOA pH 5.2, 2 
!ll of 100 mM EDTA pH 8.0, and 1 !ll of 20 /lg /Ill Glycogen), 60 !ll of cold ( -20 °C) 95 
% ethanol was then added and the tube was centrifuged at 14, 000 rpm for 15 min. The 
DNA pellet was saved by discarding the supernatant, and rinsed two times with cold ( -20 
°C) 200 !ll of 70% ethanol to remove the unincorporated dye-terminators and the residual 
salts. For each rinse, cold (-20 °C) ethanol was added and followed by an immediate 
centrifugation at 14, 000 rpm for 2 min. Finally, the DNA pellet was dried in a sealed 
vacuum centrifuge for 15 min, and then re-suspended in 20 111 of sample loading solution 
(SLS). 
2.4.4 Gel electrophoresis and data analysis on the DNA sequencer 
Each 20 111 of the purified reaction mixture was loaded and analyzed on an automated 
CEQ Beckman 8000 Genetic Analysis System (Beckman Coulter, Inc, Fullerton, CA) 
according to the manufacturer's instructions. Sequence analysis was conducted using 
software according to the manufacture's guidelines. All analyzed DNA fragments were 
sequenced in both directions. Sequence results were aligned with wild type sequences 
achieved from Genbank: (M73547), and the identified sequence variances were evaluated 
by the sequencher sequence alignment program (ACGT Codes). We are using HGVS 
nomenclature to describe mutations, i.e. numbering from the first A of the start codon, as 
opposed to the first residue given in the Genbank: entry used. 
2.5 Genomic rearrangement analysis - multiplex ligation-dependent probe 
amplification (MLPA) 
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2.5.1 MLPA test kit 
The MLP A analysis was carried out using the kit SALSA P043 APC from MRC Holland 
(Amsterdam, The Netherlands, www.mrc-holland.com). The kit contains 23-paired 
probes, which were designed for analyzing each exon of the gene in question (exons 1-
15, including exon 1 OA) including promoter regions. The promoter region was covered 
by two paired probes, and each individual ex on (ex on 1-14, plus ex on 1 OA) was analyzed 
by a single probe. The largest exon, exon 15, was assayed by five paired probes, which 
are located in different regions of exon 15. Among the five paired exon 15 probes, two 
were specifically designed for the two mutation hotspots in ex on 15 (codon 1061, codon 
1309). In addition, 14-paired probes from other chromosomal regions plus further 
controls to check for adequate quality of test DNA and efficient ligation were used as 
controls. 
2.5.2 DNA denaturation and hybridization of the SALSA-probes 
For each sample, approximately 250 ng of genomic DNA in 5 ~1 of TE buffer (1 0 mM 
Tris-HCl, pH 8.5 and 1 mM EDTA) was denatured at 98°C for 10 min. Hybridization 
was performed by adding 1.5 ~1 SALSA-probes mixture (1 finol of each synthetic probe 
oligonucleotide in TE) and 1.5 ~1 MLP A buffer (1.5 M KCl, 300 mM Tris-HCI pH 8.5, 
1 mM EDT A) to denaturized genomic DNA. The reaction was first incubated at 95°C 
for 1 min and then at 60°C for 16 hours. 
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2.5.3 Ligation reaction 
After hybridization, ligation of annealed paired probes was perfonned by adding ligase-
65 enzyme buffer (1 unit ligase-65 enzyme, 2.6 mM MgCh, 5 mM Tris-HCl pH 8.5, 
0.013% non-ionic detergents, 0.2 mM NAD) to each of the reactions. The ligation 
reaction was incubated at 54°C for 15 min and then tenninated by heating at 98°C for 5 
mm. 
2.5.4 PCR amplification of the ligated probes 
Ligated products were amplified by PCR. 30 ~1 SALSA PCR buffer was added to 10 ~1 
of the ligation reaction. 10 ~1 of polymerase mixture were added when the temperature 
reached 60°C. The polymerase mixture contained the PCR primers (10 pmol each of 
unlabelled and fluorescent dye D4-labelled primer), 2.5 nmol dNTPs and 2.5 units 
SALSA polymerase. The PCR reaction was carried out for 35 cycles (95°C for 30 sec, 
60°C for 30 sec and 72°C for 1 min). 
2.5.5 PCR products electrophoresis 
The PCR products were separated by using the CEQ8000 capillary electrophoresis 
system (Beckman Coulter, Inc, Fullerton, CA). The amplified PCR fragments from wild 
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type sequence of the APC gene presented a peak pattern of 37 and the sizes of these 
peaks ranged from 95 to 445 nt. 
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2.5.6 Data analysis 
Peak areas from each tested individual were then exported to a Microsoft Excel 
spreadsheet, which was designed to assess the ratios of each test peak relative to all other 
peaks for the same individual. Ratios of test peaks to control peaks and control peaks to 
other control peaks in each patient sample were compared to the same ratios obtained for 
two normal individuals, which were included in each run. 
For normal sequences, a dosage quotient of 1.0 was expected. If a deletion or duplication 
was present, the dosage quotient should be less than 0.6, or greater than 1.4, respectively. 
All samples with suspected deletions/duplications were confirmed in a duplicate 
analysis, and the determination of deletion/duplication was made based on consistent 
results from the duplicated analyses. 
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Chapter 3 
Results 
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3.1 Point mutation scanning- direct sequencing of the entire APC gene 
The genomic DNA from 48 patients who represent 48 different families was sequenced 
to screen for germline point mutations in the APC gene. The analyzed DNA sequence of 
the APC gene included the entire coding region, all splice sites and part of the 5' and 3' 
non-coding regions of the gene. Thirty-eight PCR amplicons were designed to cover the 
entire analyzed sequence, and the sizes of these PCR segments vary from 200 to 500 bp. 
Among the total 15 exons of the APC gene, 13 were covered by an individual PCR 
amplicon; exon 9 was divided by two overlapping PCR segments; and exon 15, the 
largest exon (6571bp), was covered by 23 overlapping PCR segments. In total, four 
truncating mutations (c.3067dupA, c.3183_3187delACAAA, c.4348C>T and c.867delC) 
and two missense variants, p.V1882D (c.5465T>A) and p.G2502S (c.7504G>A) were 
identified. In addition, a large number of silent single base pair substitutions were also 
found. The four truncating mutations were all identified from the F AP patients group ( 4 
of 9, 44 %). Three of these truncating mutations have been previously reported in other 
studies (Groden et al. 1993; Wallis et al.1999; Pang et al. 2001), and the c.867delC 
mutation is a novel finding which is specific to the Newfoundland population. The two 
missense variants were also reported in previous studies (Gregory et al. 2005; Okkels et 
al. 2006). The details of these mutations and polymorphisms from the 48 families are 
shown in Table 4. 
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Table 4. Identified sequence variants of APC gene in the Newfoundland families with 
APC - associated polyposis conditions 
Patient Clinical Mutations Polymorphisms 
75 FAP c.3165A>T (p.l10551) 
195* FAP c.5465T>A (p.V1822D) 
222 FAP c. 4348C>T (p. R1450X) c.5034A>G (p.G1678G); c.5880G>A (p.P1960P) 
884 FAP c.1635G>A (p.A545A); c.5880G>A (p.P1960P) 
1168 FAP 
1213 FAP c.1458T>C (p.Y486Y); c.1635G>A (p.A545A) 
c.5034A>G (p.G1678G); c.4479G>A (p.T1493T) 
c.5880G>A (p.Pl960P) 
10912 FAP c. 3067dupA 
11572 FAP c.3183 3187delACAAA 
at codon I 061 
12426 FAP c. 867delC c.5465T>A (p.V1822D); c.5880G>A (p.Pl960P) 
18 AFAP Exon14 del c.5034A>G (p.G1678G); c.5880G>A (p.Pl960P) 
648* AFAP 
954 AFAP 
1101 AFAP 
1167 AFAP c.4479G>A (p.T1493T); c.5034A>G (p.G1678G) 
c.5880G>A (p.P1960P) 
1212 AFAP c.l458T>C (p.Y486Y); c.l635G>A (p.A545A) 
c.5034A>G (p.Gl678G); c.5465T>A (p.V1822D) 
c.5880G>A (p.P1960P) 
1215 AFAP c.l458T>C (p.Y486Y); c.1635G>A (p.A545A) 
c.5880G>A (p.Pl960P) 
1320 AFAP c.l458T>C (p.Y486Y); c.1635G>A (p.A545A) 
c.5465T>A (p.V1822D); c.5880G>A (p.Pl960P) 
1606 AFAP c.5465T>A (p.V1822D) 
2052 AFAP 
10620 AFAP c.1458T>C (p.Y486Y) 
11160 AFAP c.1458T>C (p.Y486Y); c.1635G>A (p.A545A) 
c.5034A>G (p.Gl678G); c.5880G>A (p.P1960P) 
11417 AFAP c.5034A>G (p.G1678G); c.5880G>A (p.P1960P) 
11468 AFAP c.1458T>C (p.Y486Y); c.5465T>A (p.V1822D) 
c.7201C>T (Q.L2401L} 
11988 AFAP 
12071* AFAP c.1635G>A (p.A545A); c.5034A>G (p.G1678G) 
c.5465T>A (~V1822D}; c.5880G>A (p.P1960P} 
12082 AFAP 
12127 AFAP 
12204 AFAP 
12597 AFAP 
63 MA 
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213 MA c.1458T>C (p.Y486Y); c.5880G>A (p.P1960P) 
415 MA 
464 MA c.l458T>C (p.Y486Y); c.5034A>G (p.G 1678G) 
c.5465T>A (p.V1822D); c.5880G>A (p.P1960P) 
931 MA c.1458T>C (p.Y486Y); c.2946G>A (p.S982S) 
1096 MA c.5034A>G (p.G1678G); c.5880G>A (p.P1960P) 
1307 MA c.1458T>C (p.Y486Y); c.l635G>A (p.A545A) 
1349 MA c.5034A>G (p.G1678G) 
1685 MA c.l635G>A (p.A545A); c.5034A>G (p.G1678G) 
c.5880G>A (p.Pl960P); c.7201C>T (p.L2401L) 
1744 MA c.l4581->C (p.Y486Y); c.4479G>A (p.Tl493T) 
11069 MA c.5034A>G (p.G 1678G) 
11102 MA c.1458T>C (p. Y 486Y) ; c. 5880G>A (p.P1960P) 
11308* MA c.1458T>C (p.Y486Y); c.5465T>A (p.V1822D) 
11431* MA 
11867 MA c.5880G>A (p.Pl960P) 
12174 MA c.5465T>A (p.V1822D) 
12566 MA 
12603 MA c.5465T>A (p.V1822D); c.5880G>A (p.P1960P) 
12905 MA c.7504G>A (p.G2502S); c.7201C>T (p.L2401L) 
F AP indicates familial adenomatous polyposis 
AF AP indicates attenuated familial adenomatous polyposis 
MA indicates multiple adenomas 
Asterisk (*) indicates that DNA samples were not available for MLP A test 
In the patient 10912, a single bp (A) duplication was identified from exon 15 at 
nucleotide position 3067 (c. 3067dupA) (Figure lla), which causes an mRNA reading 
frameshift after the duplicated nucleotide (A), and generates a novel stop codon at codon 
1028. Patient 10912 was diagnosed as classical FAP at age 11 based on the clinical 
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finding of 1 00-1000 adenomas and congenital hypertrophy of retinal pigment epithelium 
(CHRPE), as well as family history of polyposis and I or CRC. 
Patient 11572 was shown to carry a five bp deletion in the exon 15 
(c.3183_3187delACAAA) which leads to a mRNA reading frameshift starting from 
codon 1061 and generating a stop codon at codon 1062 (Figure llb). Patient 11572 was 
an F AP patient. He had over 1000 polyps in his colon and duodenum at age 31. He had 
no family history of polyposis and /or CRC, and therefore, the identified 
c.3183 _3187delACAAA mutation may be due to a "de novo" event. 
A single base pair (C) deletion in exon 8 (c.867delC) was detected in FAP patient 12426. 
This single base pair deletion caused a mRNA reading frameshift starting from codon 
289, and a stop codon was generated at codon 292 (Figure 11 C). This patient had a 
medulloblastoma and colorectal adenomas at age 25. She also suffered from desmoid 
disease and had a family history of polyps and CRC. 
Patient 222 was found to carry a C>T transition at nucleotide position 4348 (c. 
4348C>T), which changes codon 1450 from CGA for arginine to a stop codon, TGA, in 
exon 15 (p.R1450X). This patient was diagnosed as classical FAP at age of36 because of 
the clinical findings of over 1000 colorectal polyps, and a number of extracolonic 
manifestations including desmoids, osteomas and epidermoid cysts. He developed colon 
cancer at age 49. 
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Two known missense variants, c. 5465 A>T (p. V1882D), and c. 7504G>A (p. G2502S) 
were detected in our studied patients. The missense variant, c. 7504G>A (p. G2502S) 
was identified only in patient 12905 with multiple adenomas. The missense variant, c. 
5465 A>T (p. V1882D) is a common APC variant, which was found in 13 of our 48 
patients (27%). The frequency of this missense change in subgroups of patients with 
FAP, AFAP and multiple adenomas was 22% (2/9), 25% (5/20) and 36% (7/19) 
respectively. These two missense changes have been previously reported but the effect of 
these variants remains unclear. 
In addition to the truncating and missense changes, we also detected eight silent variants 
in our study patients. These silent variants were all caused by single base substitutions in 
the coding region. These silent variants include c.1458 T>C (p.Y486Y), c.l635 G>A 
(p.A545A), c.2946G>A (p.S982S), c.3165A>T (p.Il0551), c.4479G>A (p.T1493T), 
c.5034 A>G (p.G1678G), c.5880 G>A (p.P1960P) and c.7201C>T (p.L2401L). Among 
these variants, c.2946G>A (p.S982S), c.3165A>T (p.110551), c.4479G>A (p.T1493T) 
and c.7201C>T (p.L2401L) are novel, and the others are previously known. 
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Table 5. Frequencies of the identified sequence variants of APC gene in the 
Newfoundland patients with APC- associated polyposis conditions 
Silent variants Missense variants Frequencies (%) 
c.l458 T>C (p.Y486Y) 31.3 
c.1635 G>A (p.A545A) 18.8 
c.2946G>A (p.S982S)* 2.1 
c.3165A>T (p.110551)* 2.1 
c.4479G>A (p.T1493T)* 6.2 
c.5034 A>G (p.Gl678G) 33.3 
c.5880 G>A (p.P1960P) 43.8 
c.7201C>T (p.L2401L)* 8.3 
c.5465T>A (p.Vl822D) 29.2 
c.7504G>A (p.G2502S) 2.1 
Asterisks (*) indicate that the silent variants are novel 
t;1 
Figure 11 a. Sequence result of mutation c. 3067 dupA (patient 1 0912) 
c. 3183-3187delACAAA 
g;; 100 IE 
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Figure llb. Sequence result of mutation c. 3183-3187delACAAA (patient 11572) 
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c. 867deiC 
Figure llc. Sequence result of mutation c. 867deiC (patient 12426) 
231] 
lCTCAA.A.C 
' 
c. 4348C>T 
Figure lld. Sequence result of mutation c.4348C>T (R1450X) (patient 222) 
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c. 5465T>A 
Figure lle. Sequence result of missense mutation c.5465T>A (p.Vl822D) 
c. 7504G>A 
Figure llf Sequence result of missense mutation c.7504G>A (p.G2502S) 
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3.2 Searching for genomic rearrangements in APC- MLP A analysis 
To search for APC germline mutations caused by exon deletion and duplication, MLP A 
analysis was carried out for 35 patients in whom no point mutation had been found by 
sequence analysis. Patient 11572 who was known to have a 5 bp deletion in exon 15 
( c.3183 _3187delACAAA) was also included as a positive control for MLP A analysis. 
Using the commercial kit for analysis of APC gene, MLPA analysis was performed to 
examine the entire APC gene including the promoter region. For exons 1-14, there was 
one PCR segment for each individual exon. Promoter region was divided into two PCR 
segments, and exon 15 was divided into three PCR segments, 15-1, 15-2, 15-3. Two 
additional PCR fragments were designed specifically to identify the two mutational 
hotspots [the 5 bp deletion at codon 1061(c.3183_3187delACAAA) and the 5 bp deletion 
at codon 1309 (c. 3927_3931delAAAGA)] in exon 15 of the APC gene. Based on the 
data from previous studies (Bunyan et al. 2004), an exonic deletion is suggested if the 
tested peak area is reduced greater than 40% compared with the controls. Our results 
showed that the peak area representing exon 14 in patient 18 was reduced more than 60% 
compared with the normal controls (Figure 12a), which was evident by both visual 
examination and calculation of peak areas. Therefore, a heterozygous exon 14 deletion 
was determined in patient 18. This patient was diagnosed as AF AP at age of 54 based on 
the findings of colorectal adenomas (at range of 10-100), CRC, gastric adenomas and 
family history of polyps. 
Our MLPA analysis also detected a heterozygous 5 bp deletion at codon 1061 in patient 
11572 (Figure 12b ), which was consistent with the result obtained from our sequencing 
analysis. The peak area representing the 5 bp deletion (c.3183_3187delACAAA) at 
codon 1 061 was reduced 52% compared with the corresponding control. This result for a 
known mutation provided good quality control for our MLP A analysis. The MLP A 
analysis was repeated to confirm these results. 
56 
soooo 
50000 
-40000 
30000 
20000 
10000 
0 c c c c c c c c c c c c c 
90000 
80000 
70000 
soooo 
!50000 
40000 
30000 
20000 J 
1000: ~.......IL-LL~....LL..JL,.~....,_.._~.II-.II.....JII....IL--I<'-!'--U.......U..~....U.....JI-~...11-.JI.-~u.....J~U-JI......I. ......... '-!'--U.......U..-U..~~~~ 
c c c c c c c c c c c cc 
Figure12 a. MLPA result from wild type control (above) and patient 18 (below) with 
heterozygous APC exon 14 deletion. An arrow denotes the APC ex on 14-specific peak. 
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Figure12b. MLPA result from wild type control (above) and patient 11572 with 
heterozygous 5 bp deletion at codon 1061 of the APC gene 
(c.3183_3187delACAAA). An arrow denotes the codon 1061-specific peak. 
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Chapter 4 
Discussion and Conclusion 
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4.1 Sequence variants found in the present study 
To date, over 1,000 different germline mutations have been reported in patients with 
APC-associated polyposis conditions (http://perso.curie.fr/tsoussi, and 
http://www.cancer-genetics.org). The majority of the mutations cause a premature 
truncation of the APC protein, usually through single amino-acid substitutions (nonsense 
mutations) or frameshifts (small deletions or insertions). The reported mutations are 
spread throughout the gene, but are predominantly located in the 5' half of the gene. The 
most common germline APC mutations are the two 5-bp deletions, which result in 
frameshiftmutations at codon 1061 (c.3183_3187delACAAA) and 1309 
(c.3927_3931delAAAGA) (Beroud et al. 1996). In the present study, we identified 15 
different sequence variants of the APC gene by screening 48 Newfoundland patients with 
FAP/AFAP/multiple adenoma representing 48 unrelated families. The sequence variants 
we identified include three small deletions/duplication (c.3067dupA, c867delC, 
c3183_3187delACAAA), one nonsense change (p. R1450X), one exonic deletion (del 
exon 14), two missense changes (p. V1822D and p. G2502S) and eight silent variants. 
Protein truncating mutations 
Sequence variants caused by small deletion/duplication ( c.3183 _3187delACAAA, 
c.867delC, del exon 14 and c.3067dupA) and nonsense change (p. Rl450X) are predicted 
to cause protein truncation of APC. To date, the c.3067dupA, c.3183_3187delACAAA, 
del exon 14 and p.R1450X have been previously reported as causative mutations for 
FAP. However, the c.867delC is a novel finding. Because the single base pair deletion 
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would result in a frameshift, we think that the c.867delC should be a causative mutation 
for F AP in this patient. The majority of reported germline mutations found in patients 
with F AP cause protein truncation (Mandl et al. 1994; Paffenholz et al. 1994; van der 
luijt et al.1997; Wallis et al. 1999; Gebert et al. 1999; Friedl et al. 2001). Miyoshi et al 
(1992) examined 79 unrelated patients with F AP and detected germline mutations of the 
APC gene in 53 patients (67%), and 92% of these mutations were predicted to cause 
truncation of the APC protein. Through investigating 123 unrelated families with PAP, 
Gebert et al (1999) identified 85 different germline mutations from these families. All of 
these mutations were distributed in the 5' half of the APC gene between codons 213 and 
1581, and were predicated to cause protein truncation of APC. Our results suggest that 
the genetic predisposition for PAP in Newfoundland population is similar to other 
populations, which are mainly due to loss of function mutations of APC gene. The exon 
14 deletion identified in one AF AP patient is also predicted to cause protein truncation, 
but we do not know, at this moment, if this deletion causes a reading frameshift or not. 
We assume this deletion may at least cause partial loss of the APC function. 
These five truncating mutations are all located in the 5' half of APC gene between codon 
289 and 1450. Three of them are clustered at the 5' end ofexon 15 between codon 1023 
and 1450. 
Missense variants 
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Disease-causing mtssense changes of APC gene are rarely reported because the 
functional implications of missense changes are often unclear. Generally speaking, 
missense alteration may be functionally important if it alters the polarity of an amino acid 
in highly conserved regions or in the functional domains of the encoded protein. In the 
APC protein, there are two amino acid repeat regions responsible for B-catenin binding 
and down-regulation (Bright-Thomas and Hargest. 2003). The B-catenin down-regulation 
domain is located in the region between codon 1324 and codon 2075 that contains seven 
20 amino acid binding repeats. At least the first three binding repeats located between 
codons 1286 and 1513 are required for efficient B-catenin down-regulation. 
So far, only a few APC missense variants have been associated with F AP (Nishisho et al. 
1991; Dobbie et al.l994; Laken et al. 1997; van der Luijt et al. 1997; Frayling et al.l998; 
Ficari et al. 2000). The missense variant, p.I1307K, for example, has been associated 
with increased risk of CRC but not necessarily polyposis (Laken et al. 1997). This 
missense variant is caused by a T>A transversion at nucleotide 3920 that converts the 
sequence AAATAAAA to an (A)8 tract in the APC coding region. This change is 
presumed to cause failure of the cellular transcriptional or translational machinery, thus 
resulting in somatic mutations by slippage when DNA replicates. In another example, the 
missense variant, E1317Q was reported to be associated with colon adenomas and /or 
colon cancer in a number of studies (Frayling et al. 1998; Lamlum et al. 2000; Popat et al. 
2000; Hahnloser et al. 2003), but an opposite result was also reported. Fidder's (2005) 
study on Jewish patients showed that the carrier frequencies of El317Q among CRC 
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patients and controls were approximately identical, which indicated that the E1317Q 
variant played little if any role in colorectal cancer susceptibility. 
Two missense variants, V1822D and G2502S, which were identified in the present study 
have been previously reported and both of them are located at the 3' half of the APC 
gene. The V1822D variant is situated between the third and fourth binding repeats within 
the B-catenin down-regulation domain, and therefore, is unlikely to crucially effect B-
catenin degradation (Bright-Thomas and Hargest. 2003; Rubinfeld et al. 1997). The 
V1822D variant was suggested to be a low-penetrance allele that increased risk of 
developing colorectal cancer based on an early study (Wallis et al 1999). However, such 
an association was not confirmed in several later association studies (Slattery et al. 2001; 
Tranah et al 2005). The G2502S variant is located outside the region for coordination of 
~-catenin down-regulation, and therefore it may not have an appreciable affect on· ~­
catenin degradation (Bright-Thomas and Hargest. 2003; Rubinfeld et al. 1997). The 
G2502S might be associated with more subtle abnormalities in processing of RNA 
transcripts which in turn could result in the expression of differentially spliced forms of 
the APC gene, which might interfere with the functional activity of the APC protein 
(Rodney et al. 2004). However, a recent large cohort study failed to associate the G2502S 
variant with either colorectal cancer or adenoma {Tranah et al. 2005). 
The V1822D variant was reported to have a 22% to 25% allele frequency in the general 
population (Slattery et al. 2001; Tranah et al. 2005), which suggested that it was a 
common APC variant. The G2502S variant showed an allele frequency of 10% in 
Caucasians (SNP 500; http://snp500cancer.nci.nih.gov). In the present study, the V1822D 
variant was detected in 14 out of 48 patients, and the G2502S variant was only found in 
one patient, which gave allele frequencies of 29.2 % for V 1822D and 2.1 % for G2502S 
respectively. The allele frequency of G2502S in Newfoundland patients is lower than in 
other publications (SNP 500; http://snp500cancer.nci.nih.gov). This could either be a 
result of a statistical bias due to the small sample size used in our study or it is possible 
that there is a true lower allele frequency of this variant in Newfoundland population. Our 
continuing study for genotyping these two variants in more patients and a large number 
of controls from the local population is underway, which will help to determine the allele 
frequencies of V1822D and G2502S in both Newfoundland patients and the normal 
population. 
Silent variants 
Single nucleotide substitution in the coding region of a gene may or may not lead to the 
change of an amino acid. Those that do not change the amino acid are known as silent 
variants. In general, the majority of the. silent variants are polymorphisms, and do not 
play a role in disease. However, recent evidence suggests that some silent variants could 
be pathogenic because of skipping of an exon. In this situation, a silent variant usually 
occurs in the region containing a transcriptional regulatory element necessary for proper 
splicing known as an exonic splicing enhancer (ESE) (Aretz et al. 2004). Alteration of an 
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ESE even without changing an amino acid can cause exon skipping. Therefore, to 
determine the consequence of a missense or a silent variant, it is necessary to consider the 
possible amino acid change, and also whether there is a change in size of the transcript. 
The ESEs have been reported in a number of genes, such as the fibrillin-1 gene, the 
MLHJ gene, and the human phenylalanine hydroxylase gene (Liu et al. 1997; Nystrom-
Lahti et al. 1999; Chao et al. 2001), and mutations in these ESEs are linked to the 
corresponding diseases. Montera et al (2001) described a distinct severe FAP phenotype 
within a family that was attributed to a silent mutation, c.1869G>T (p.R623R), in the 
middle of APC exon 14. This silent nucleotide substitution was related to the disruption 
of putative ESE motifs, inducing complete skipping of exon 14 and leading to a stable 
truncated APC protein. Aretz et al (2004) examined five rare novel missense or silent 
variants in the APC gene located close to splice sites by transcript analysis, and found 
that four of these variants resulted in ex on skipping. These findings show a possible new 
model of APC causative mutations and demonstrate the existence of exonic sequence 
elements modulating the splicing of the APC gene. This emphasizes the importance of 
investigating missense and silent mutations. In the present study, we identified eight 
silent variants in the APC gene. Four of them were previously known and four were 
novel. The variants, 5880G>A (p.P1960P) and 5034A>G (p.G1678G) have prevalences 
of 43.8 % and 33.3%, respectively in our studied patients. In the near future, the 
prevalences of these two silent variants in the general Newfoundland population will be 
investigated and compared. 
To determine if these silent variants predispose to polyposis conditions, we will further 
characterize these variants in the second phase of this study, which will include family 
study and transcript analysis of these variants. A family study will investigate if these 
silent variants cosegregate with the clinical conditions in the families. The transcript 
study will help us to investigate a possible ESE. 
Genomic deletions 
In our study, an exonic deletion was detected in one patient with AF AP. This sequence 
alteration was the only convincing pathogenic mutation found in AF AP patients. The 
ex on 14 deletion has been reported in patients with F AP but not in patients with AF AP 
(Su et al.2000; Sieber et al, 2002; Michils et al. 2005). It may indicate that exon 14 
deletion in this case is an inframe deletion rather than a frameshift change. Therefore, 
mutation study of the APC gene in AF AP patients should pay more attention to genetic 
defects that may mildly affect the gene function, such as inframe deletions, missense 
changes and some of the silent variants. Direct sequencing should not be the only 
method for mutation study of the APC gene in patients with AF AP and multiple 
adenomas. 
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4.2 Mutation detection rate 
Typical F AP patients have been reported to have a 30-85 % detectable mutation rate in 
the APC gene depending on the patients examined and the methods used for mutation 
analysis (van der luijt et al. 1997; Wallis et al. 1999; Friedl et al. 2001; Heinimann et al. 
1998; Giarola et al. 1999). The mutation detection rate in patients with F AP is usually 
much higher than that in patients with AF AP (Sieber et al. 2002; Aretz et al. 2005; 
Michils et al. 2005). In the present study, the five truncating sequence alterations 
(nonsense mutation and frameshift mutation) can easily be recognized as causative 
mutations, which give a mutation detection rate of 10.4% in the total of 48 studied 
patients. Among the five truncating mutations, four were detected in the patients with 
F AP, and one in a patient with AF AP, which gives a mutation detection rate of 44% ( 4/9) 
in patients with FAP, and 5%(1120) in patients with AFAP. Obviously, the detection rate 
of APC mutation in our study is lower than those in previous studies. We consider several 
following possibilities that may have contributed to the low mutation detection rate in our 
study. 
a) 81% (39/48) of our patients were diagnosed as either AF AP or multiple adenomas. 
Based on the results from previous studies, approximately 10-30% of patients with 
FAP and up to 90% of those with AFAP/multiple adenomas remain without a 
detectable APC germline mutation. These families are APC mutation-negative despite 
applying different screening methods (Nagase and Nakamura. 1993; Miyoshi et al. 
1992; Groden et al. 1993; Armstrong et al. 1997; Giardiello et al. 1997; van der Luijt 
F.7 
et al. 1997; Scott et al. 2001; Spirio et al. 1993; van der Luijt et al. 1996; Lamlum et 
al. 2000; Heinimann et al. 2001; Friedl et al. 2001; Moisio et al. 2002; Sieber et al. 
2002). Similar to other studies, detection rates of the APC mutation in patients with 
AFAP and multiple adenomas in our present study are 5% (1/20) and 0% (0/19), 
respectively. This suggests that the major genetic predisposition to AF AP and 
multiple adenomas in our group of families may be different from that for F AP. Such 
a difference may result from either a different way to cause APC function change that 
cannot be detected by the currently used method, or different unknown mutant 
gene(s) in the same or a different pathway. 
b) Our sequencing analysis was restricted to the coding sequences and intron/exon 
junction areas of the APC gene. Therefore, we cannot exclude the possibility that 
some undetectable sequence alterations in the intronic regions and promoter region 
may play a role in the clinical conditions of the patients. Powell et al (1993) reported 
that the expression of the APC alleles was significantly reduced in three out of eleven 
APC mutation-negative F AP patients. This suggests that some sequence alterations in 
the nonexamined sequences may have a significant influence on gene expression. 
c) Germline defects in gene(s) other than APC gene may be involved in the etiology of 
the clinical conditions in some of our patients. Mutations in the gene(s) that interact 
with the APC protein, or regulate the expression of APC may also predispose to F AP. 
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Some evidence supports the presence of at least one additional gene apart from APC 
causing F AP. This hypothesis is suggested based on the observations that 
approximately 20% of clinically typical FAP kindreds fail to show any APC 
mutations even with the best available techniques (Powell et al. 1993; Laken et al. 
1999). Genes involved in the Wnt-signaling transduction pathway, such as a-catenin 
gene (Mcpherson et al.1994 ), ~-catenin gene (Kraus et al. 1994 ), as well as axin 1 and 
axin 2 gene, have been suggested as the potential candidates (Peifer. 1996). There is 
also evidence that the base-excision-repair gene, Mut Y homolog (MYH), encoding a 
DNA glycosidase can be associated with the susceptibility to FAP (AI-Tassan et al. 
2002). 
d) Patients with fewer (10-100) colorectal adenomas obviously represent a 
heterogeneous and yet poorly characterized group between FAP and HNPCC. The 
phenotype in some AF AP patients sometimes can mimic HNPCC (McGarrity et al. 
2000; Scott et al. 1996), and at some point AF AP was thought to be a variant of 
HNPCC (Lynch et al. 1996). Some HNPCC cases could be easily misdiagnosed as 
AF AP patients if family and medical history is incomplete (Cao et al. 2002; Lynch et 
al. 1996; Lynch et al. 1992). 
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4.3 Summary 
Using direct DNA sequencing and MLPA, we perfonned mutation scanning of the APC 
gene in 48 selected Newfoundland patients with FAP/AFAP/multiple adenomas. These 
selected patients represent 48 unrelated families. In total, five truncating mutations (four 
frameshift mutations and one exonic mutation) were identified in five families and two 
missense variants were detected in 15 families. In addition, eight silent variants were 
also found and four of them are novel. All the frameshift changes were identified in the 
FAP patients (44 %). A truncating mutation caused by deletion of exon 14 was found in 
one patient with AF AP, this being the only convincing mutation found in our patients 
with AFAP (5%). Four of these mutations have been previously reported (Groden et al. 
1993; Wallis et al.1999; Pang et al. 2001), and the mutation, c.867delC, is a novel 
finding. The two identified missense variants were also previously reported (Gregory et 
al. 2005; Okkels et al. 2006). Among the eight silent variants found in our patients, four 
are novel. 
Our results suggest: 1) the genetic predisposition to FAP in Newfoundland population is 
similar to that identified in other populations, which is mainly due to loss of function 
changes of the APC gene; 2) gennline APC mutation may not be the major cause for the 
conditions AF AP/multiple adenomas; and 3) the search for exonic deletion of the APC 
gene is necessary for mutation study of patients with AFAP. Identification of the 
causative gennline mutations of the APC gene in Newfoundland patients with F AP or 
AF AP or multiple adenomas will lead to establishment of a direct testing method for each 
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of the identified mutations, which will be transferred into clinical service. The established 
predictive genetic testing will then be used to determine the risk status for consenting at-
risk family members to provide proper prevention and/or treatment options. 
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